While current guidelines do not recommend endovascular treatment for MeVOs, techniques are improving rapidly, making these occlusions more safely accessible. As such, clinical practice is evolving, and MeVOpatients are increasingly being treated. This practice is heterogeneous though, and experiences are not reported on a large scale. We think that treatment of these patients could be the next frontier in improving outcomes of acute stroke.
The ESCAPE NEXT Trial is a multicentre, randomized, double-blinded, placebo-controlled, parallel group, single-dose design to determine the efficacy and safety of intravenous Narinitide in subjects with acute ischemic stroke not recieving or ineligable for alteplase undergoing endovascular thrombectomy.